Loading...
Loading...
GILD| Name | Value |
|---|---|
| Revenues | 6,686.0M |
| Cost of Revenue | 1,552.0M |
| Gross Profit | 5,134.0M |
| Operating Expense | 2,832.0M |
| Operating I/L | 2,302.0M |
| Other Income/Expense | -6,788.0M |
| Interest Income | 0.0M |
| Pretax | -4,486.0M |
| Income Tax Expense | -315.0M |
| Net Income/Loss | -4,170.0M |
Gilead Sciences, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines for unmet medical needs. The company's product portfolio includes treatments for HIV/AIDS such as Biktarvy, Genvoya, and Truvada, as well as medications for liver diseases like Epclusa and Harvoni. Additionally, Gilead offers products for hematology, oncology, and cell therapy patients, including Yescarta and Tecartus. The company also provides treatments for pulmonary arterial hypertension and chronic angina. Gilead Sciences generates revenue through the sale of these pharmaceutical products and has collaboration agreements with several other biotech and pharmaceutical companies.
